Meitheal Pharmaceuticals, Inc. announces the acquisition of North America rights to CONTEPO™ (fosfomycin for injection) from Nabriva Therapeutics. This strategic addition to Meitheal's product portfolio aims to address the significant unmet need around increasing antibiotic resistance and to deliver a consistent supply of high-quality antibiotic to patients and providers in need of innovative options for drug-resistant urinary tract infections.